AAV-IL-10
AAV-IL-10 has been studied in 1 paper since 2020: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 30, 2020: “IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis”.
1 paper studies it2 findingsUpdated
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Institute of Neurological Disorders and Stroke and 1 more
- Animals1
What did studies of AAV-IL-10 find?
2Studies of AAV-IL-10 measured 2 outcomes; the most studied are immune response (1 study) and lifespan (1).
Immune response
upin mice1
1 study
Immune response
upin mice1
AAV-IL-10 activates immune response in mice.
“transcriptomic analysis revealed induction of innate immunity and phagocytotic pathways in presymptomatic SOD1-G93A mice expressing IL-10 + M3 or IL-10 alone”
Animalsin presymptomatic SOD1-G93A mice
Scientific reports
Lifespan
upin mice1
1 study
Lifespan
upin mice1
AAV-IL-10 extends lifespan in mice.
“recombinant adeno-associated virus (AAV)-mediated expression of IL-10, alone, or in combination with M3, resulted in modest extension of lifespan relative to control SOD1-G93A cohort”
Animalsin SOD1-G93A mice
Scientific reports